echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Antengene Announces Approval of Phase I Clinical Trial Application of ATG-101 in China

    Antengene Announces Approval of Phase I Clinical Trial Application of ATG-101 in China

    • Last Update: 2022-04-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    SHANGHAI, CHINA & HONG KONG, March 10, 2022 /PRNewswire/ -- A leading commercial-stage innovative biopharmaceutical company dedicated to developing, manufacturing and marketing first-in-class and/or best-in-class hematologic and solid tumor therapies – Antengene Pharma Co.


    As a novel PD-L1/4-1BB bispecific antibody, ATG-101 can block immunosuppressive PD-L1/PD-1 binding while conditionally activate 4-1BB co-stimulatory signal, thereby activating anti-tumor Immune effector cells enhance safety while enhancing efficacy


    This clinical study is led by Shanghai Dongfang Hospital and is planned to be carried out in 4 research centers in China


    The principal investigator, Professor Guo Ye, deputy director of the Department of Oncology at Shanghai Dongfang Hospital and director of the Phase I Clinical Center, said: "At present, many patients with malignant tumors are resistant or difficult to existing treatments (including chemotherapy, targeted therapy, and immunotherapy).


    Dr.


    About ATG-101

    ATG-101 is a novel PD-L1/4-1BB bispecific antibody being developed for the treatment of metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma (B-NHL)


    About Antengene

    Antengene Pharmaceuticals Co.


    forward-looking statements

    Forward-looking statements made herein relate only to events or information as of the date on which they are made


    Source: Antengene Pharmaceuticals Ltd.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.